BI 655064, another antagonistic anti-CD40 antibody was safely tested on healthy volunteers [110], yet failed to meet the primary endpoint (clinical improvement) in patients with rheumatoid arthritis [111]. This evidence concerns the gene CD40 and rheumatoid arthritis.